10.1038/s41380-019-0414-4 146 SbriniG.HanswijkS
The topline results from the ESSENCE trial of semaglutide showed that a once-weekly 2.4mg dose of the drug was better than placebo at resolving MASH and improving liver fibrosis, meeting its primary efficacy objectives
We dont fully understand this yet, but it is important to keep in mind when considering weight loss distribution in shorter trials and especially when drawing conclusions at early timepoints
Importantly, Klinic accepts insurance and navigates the prior authorization process on your behalf, ensuring you can focus on achieving your health goals without administrative hurdles
The newer approvals marked a game changer for treating obesity and weight gain, which had been widely stigmatized and thought of primarily as a willpower issue, Harris said, when genetic or biological factors can cause some patients to gain weight more easily and have more difficulty losing weight